Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 29407-1-AP - Provider product page

- Provider
- Proteintech Group
- Product name
- FAM111B antibody
- Antibody type
- Polyclonal
- Description
- FAM111B antibody (Cat. #29407-1-AP) is a rabbit polyclonal antibody that shows reactivity with Human and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Pan-cancer analysis identifies FAM111B as a biomarker for immune suppression microenvironment in low-grade gliomas.
FAM111B enhances glycolysis and promotes metastasis of prostate cancer by upregulating LDHA.
The ELF1/IGF2BP2/FAM111B Cascade Drives Colorectal Cancer Progression and Ferroptosis Resistance.
PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B.
Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance.
Pan-Cancer Analysis of the Tumorigenic Effect and Prognostic Diagnostic Value of FAM111B in Human Carcinomas.
Silencing of FAM111B inhibited proliferation, migration and invasion of hepatoma cells through activating p53 pathway.
Clinicopathological features, prognostic significance, and associated tumor cell functions of family with sequence similarity 111 member B in pancreatic adenocarcinoma.
Wang Z, Li L, Wang B, Liu Z, Yin X, He D, Li Y, Liu Q, Xin T
Translational cancer research 2026 Feb 28;15(2):89
Translational cancer research 2026 Feb 28;15(2):89
FAM111B enhances glycolysis and promotes metastasis of prostate cancer by upregulating LDHA.
He Q, Li H, Cong Y, Chen K, Cheng L, Lv F, Zhang P, Ju Y, Yu Z, Chen J, Wang C, Song Y, Li X, Chen L, Xing Y
Neoplasia (New York, N.Y.) 2025 Nov;69:101227
Neoplasia (New York, N.Y.) 2025 Nov;69:101227
The ELF1/IGF2BP2/FAM111B Cascade Drives Colorectal Cancer Progression and Ferroptosis Resistance.
Yin D, Cao L, Hua M, Chen Y
Clinical and experimental pharmacology & physiology 2025 Dec;52(12):e70090
Clinical and experimental pharmacology & physiology 2025 Dec;52(12):e70090
PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B.
Yin J, Qin F, Chen H, Wang X, Xia R, Ni B, Wang H
Medical oncology (Northwood, London, England) 2024 Nov 18;42(1):6
Medical oncology (Northwood, London, England) 2024 Nov 18;42(1):6
Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance.
Wang H, Wang H, Chen J, Liu P, Xiao X
Cellular oncology (Dordrecht, Netherlands) 2024 Feb;47(1):343-359
Cellular oncology (Dordrecht, Netherlands) 2024 Feb;47(1):343-359
Pan-Cancer Analysis of the Tumorigenic Effect and Prognostic Diagnostic Value of FAM111B in Human Carcinomas.
Wu H, Liang C
International journal of general medicine 2023;16:1845-1865
International journal of general medicine 2023;16:1845-1865
Silencing of FAM111B inhibited proliferation, migration and invasion of hepatoma cells through activating p53 pathway.
Li F, He HY, Fan ZH, Li CM, Gong Y, Wang XJ, Xiong HJ, Xie CM, Bie P
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2023 Dec;55(12):1679-1689
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2023 Dec;55(12):1679-1689
Clinicopathological features, prognostic significance, and associated tumor cell functions of family with sequence similarity 111 member B in pancreatic adenocarcinoma.
Gong Q, Dong Q, Zhong B, Zhang T, Cao D, Zhang Y, Ma D, Cai X, Li Z
Journal of clinical laboratory analysis 2022 Dec;36(12):e24784
Journal of clinical laboratory analysis 2022 Dec;36(12):e24784
No comments: Submit comment
No validations: Submit validation data